Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14016290 | 0.90 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL12225437 | 0.72 | ALDH5A1 (0.42) | ALDH1A1MAPTBLMNPSR1 | |
| SCHEMBL1249256 | 0.71 | CYP3A4 (0.33) | MEN1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL10705397 | 0.70 | KDM4E (0.39) | MEN1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12945238 | 0.70 | ALDH1A1 (0.34) | MEN1ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13960060 | 0.69 | IDO1 (0.32) | — | |
| SCHEMBL12188523 | 0.69 | TDP1 (0.42) | MEN1ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL12094217 | 0.68 | HSP90AA1 (0.32) | — | |
| SCHEMBL18977864 | 0.68 | MEN1 (0.37) | MEN1CYP3A4TSHRMAPK1KMT2A | |
| SCHEMBL13051720 | 0.68 | CYP3A4 (0.40) | MEN1USP2ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155747-B1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | CNR1, CNR2, GPR18 | MEN1 1832/4885USP2 3913/4885ALDH1A1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.